Free Trial

Entera Bio (ENTX) to Release Earnings on Friday

Entera Bio logo with Medical background

Key Points

  • Entera Bio is set to release its Q2 2025 earnings data on August 8th, with analysts predicting a loss of ($0.11) per share.
  • In its last earnings report on May 9th, Entera Bio reported a loss of ($0.06) per share, which was better than the expected ($0.07).
  • The company's stock has recently seen a 4.5% decline and it currently trades at $1.93, with a market cap of approximately $87.72 million.
  • Interested in Entera Bio? Here are five stocks we like better.

Entera Bio (NASDAQ:ENTX - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.04 million during the quarter. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 95.10%. On average, analysts expect Entera Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Entera Bio Trading Up 1.0%

ENTX traded up $0.02 during trading on Friday, hitting $1.95. 30,488 shares of the company traded hands, compared to its average volume of 267,502. Entera Bio has a 1 year low of $1.41 and a 1 year high of $2.79. The company has a market cap of $88.63 million, a PE ratio of -7.50 and a beta of 1.52. The stock's 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.02.

Entera Bio Company Profile

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

See Also

Earnings History for Entera Bio (NASDAQ:ENTX)

Should You Invest $1,000 in Entera Bio Right Now?

Before you consider Entera Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.

While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines